Benefits in the lipid profile after substitution of abacavir for stavudine:: A 48-week prospective study

被引：8

作者：

García-Benayas, T

Blanco, F

Alcolea, A

De la Cruz, JJ

González-Lahoz, J

Soriano, V

机构：

[1] Hosp Carlos III, Infect Dis Serv, Madrid 28035, Spain

[2] Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Madrid, Spain

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2004年 / 20卷 / 12期

关键词：

D O I：

10.1089/aid.2004.20.1289

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Stavudine (d4T) has been associated with lipoatrophy and hyperlactatemia. In recent studies, d4T has also been related to both hypercholesterolemia and hypertriglyceridemia. Replacing d4T with another nucleoside analogue such as abacavir (ABC) may reduce lactate levels and improve lipoatrophy in the long term. However, the impact of this strategy on the lipid profile is still unclear. In a prospective and randomized study, fasting lipids were examined over 48 weeks in 112 subjects on d4T regimens, 49 of whom replaced d4T with ABC. The substitution of ABC for d4T was found to be safe and provided a reduction in both LDL cholesterol and the total cholesterol (TC)/HDLc ratio, which might impact favorably on cardiovascular risk.

引用

页码：1289 / 1292

页数：4

共 14 条

[11]

MARTIN A, 2003, 5 INT WORKSH ADV DRU

[12] Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection [J].

Martinez, E ;

Arnaiz, JA ;

Podzamczer, D ;

Dalmau, D ;

Ribera, E ;

Domingo, P ;

Knobel, H ;

Riera, M ;

Pedrol, E ;

Force, L ;

Llibre, JM ;

Segura, F ;

Richart, C ;

Cortes, C ;

Javaloyas, M ;

Aranda, M ;

Cruceta, A ;

de Lazzari, E ;

Gatell, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (11) :1036-1046

[13] A 48-week, randomized, open-label comparison of three Abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy [J].

Moyle, GJ ;

Baldwin, C ;

Langroudi, B ;

Mandalia, S ;

Gazzard, BG .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (01) :22-28

[14]

STASZEWSKI S, 2003, 10 C RETR OPP INF BO

← 1 2 →